ReviewRecent patents on endocrine, metabolic & immune drug discovery2017
The Regulatory Roles of Mitogen-Activated Protein Kinase (MAPK) Pathways in Health and Diabetes: Lessons Learned from the Pancreatic β-Cell.
Review in Recent patents on endocrine, metabolic & immune drug discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 82 citations in OpenAlex.
- White adipose tissue expansion as the driver of insulin resistance and secondary endocrine disturbances in obesity- a narrative review.Diabetology & metabolic syndrome · 2026Review
- RIP kinase inhibition with Necrostatin-1 improves human marginal mass islet graft survival and function for the management of type 1 diabetes.Cell death & disease · 2026Article
- Deconstructing the RAGE signaling maze: the molecular key to opening a new dimension of ovarian anti-aging.Experimental & molecular medicine · 2026Review
- Integrated Strategy Combining Real-World Data Mining, Network Pharmacology, and Molecular Docking to Decipher the Mechanism of Action of a Core Herbal Combination for Menopausal Syndrome.International journal of women's health · 2026Article
- Therapeutic potential of traditional Chinese medicine and mechanisms for the treatment of type 2 diabetes mellitus.Chinese medicine · 2025Review
- Integrative analysis of DEGs and regulatory networks in T2DM: identification of core genes and regulatory elements as novel therapeutic targets.3 Biotech · 2025Article
- Hypoxia-associated genes and metabolic abnormalities in peripheral blood mononuclear cells of type 1 diabetes mellitus patients.Hereditas · 2025Article
- Transcriptome-wide N6-methyladenosine methylation dynamic profile in type 1 diabetes progression.Epigenomics · 2025Article
- Article
- Effect ofVeterinary research forum : an international quarterly journal · 2025Article
- 3D evaluation of the extracellular matrix of hypoxic pancreatic islets using light sheet fluorescence microscopy.Islets · 2024Article
- Astaxanthin has a beneficial influence on pain-related symptoms and opioid-induced hyperalgesia in mice with diabetic neuropathy-evidence from behavioral studies.Pharmacological reports : PR · 2024Article
- The Anti-Inflammatory Roles of Vitamin D for Improving Human Health.Current issues in molecular biology · 2024Review
- Unlocking the mechanistic potential ofJournal of traditional and complementary medicine · 2024Review
- Harnessing Prebiotics to Improve Type 2 Diabetes Outcomes.Nutrients · 2024Review
- Circulating hsa-miR-320a and its regulatory network in type 1 diabetes mellitus.Frontiers in immunology · 2024Article
- The Association between Serum 25-Hydroxyvitamin D3 Levels and Pro-Inflammatory Markers in New-Onset Type 2 Diabetes Mellitus and Prediabetes.Biomolecules · 2023Article
- Hydrogen peroxide-dependent oxidation of ERK2 within its D-recruitment site alters its substrate selection.iScience · 2023Article
- Delineating mouse β-cell identity during lifetime and in diabetes with a single cell atlas.Nature metabolism · 2023Article
- Control of human pancreatic beta cell kinome by glucagon-like peptide-1 receptor biased agonism.Diabetes, obesity & metabolism · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundGlucose-stimulated insulin secretion (GSIS) from the pancreatic β-cell involves several intracellular metabolic events which lead to the translocation of insulin granules towards the membrane for fusion and release. It is well established that loss of β-cell function and decreased GSIS underlie the pathogenesis of diabetes. Evidence from several laboratories, including our own, demonstrated requisite roles of Rac1 and phagocyte-like NADPH oxidase (Nox2)-derived reactive oxygen species (ROS) in optimal function of the pancreatic β-cell, including GSIS. However, it is becoming increasingly clear that prolonged exposure of β-cells to hyperglycemic conditions, leads to sustained activation of Rac1-Nox2 signaling axis culminating in excessive generation of intracellular ROS (oxidative stress) and β-cell dysregulation and demise. Such "cytotoxic" effects of ROS appear to be mediated via the stress-activated protein kinases/mitogen-activated protein kinases (SAPK/MAPK) signaling pathways.
objectiveThis review discusses our current understanding of regulation and functions of the conventional MAPKs, namely, ERK1/2, JNK1/2 and p38MAPK.
conclusionThe MAPK pathways are activated in the presence of various stress stimuli including intracellular ROS, via distinct signaling cascades. Once activated, MAPKs participate in specific intracellular signaling processes via interaction with several downstream kinases including the MAPKactivated protein kinases (MAPKAPKs) and transcription factors including c-jun and p53. We have provided an overview of existing evidence in the islet β-cell on the regulatory roles of these MAPKs in mediating cellular responses to alterations in intracellularly generated ROS, which is mediated by the Rac1-Nox2 signaling module. Additionally, we enlisted recent patents developed to improve β-cell function in diabetes and novel pharmacological agents that target oxidative stress and MAPK pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.